Dey To Pay $280M To End Drug Price Inflation Suit

Law360, New York (December 20, 2010, 9:38 PM EST) -- Mylan Inc. subsidiary Dey Inc. on Monday agreed to pay $280 million to settle allegations that it violated the False Claims Act by inflating prices for its pharmaceutical products, marking the fourth such settlement announced by the U.S. Department of Justice in December.

The settlement with Dey resolves a qui tam suit filed in the U.S. District Court for the District of Massachusetts in 2005 by Ven-A-Care of the Florida Keys Inc., an independent pharmacy. Ven-A-Care will receive $67.2 million for blowing the whistle on the...
To view the full article, register now.